| Literature DB >> 29050818 |
José de J Guerrero-García1, Argelia E Rojas-Mayorquín2, Yeminia Valle3, Jorge R Padilla-Gutiérrez3, Víctor A Castañeda-Moreno3, Mario A Mireles-Ramírez4, José F Muñoz-Valle3, Daniel Ortuño-Sahagún5.
Abstract
The CD40/CD40L system is a binding key for co-stimulation of immune cells. Soluble form of CD40L has been widely studied as marker of inflammatory and autoimmune diseases. Here we analyze serum concentrations of sCD40L, as well as 14 cytokines, in patients with Multiple Sclerosis (MS) treated with Glatiramer acetate or Interferon beta. In the healthy control group, we found in serum a highly positive correlation between sCD40L and Interleukin (IL)-31, an anti-inflammatory Th2 cytokine. Additionally, an important reduction in IL-31 and sCD40L serum levels, as well as a significant reduction in CD40 mRNA expression and complete depletion of CD40L mRNA, detected from peripheral blood cells, was found in treated patients with MS. Therefore, sCD40L and IL-31 must be taken into account as possible prognostic markers when analyzing the disease progress of MS in order to provide more personalized treatment.Entities:
Keywords: Glatiramer acetate; IFN-β; IL-31; Multiple sclerosis; sCD40L
Mesh：
Substances：
Year: 2017 PMID： 29050818 DOI： 10.1016/j.imbio.2017.10.001
Source DB: PubMed Journal: Immunobiology ISSN： 0171-2985 Impact factor: 3.144